Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results Conference Call for February 16, 2022 at 8:30 AM ET Post published:February 1, 2022 Post category:Press Release
Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares to Release Industry-First Amanita Muscaria Tincture Post published:February 1, 2022 Post category:Press Release
Numinus Appoints New Bioscience Advisors to Advance IP Development Post published:February 1, 2022 Post category:Press Release
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus Post published:February 1, 2022 Post category:Press Release
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial Post published:February 1, 2022 Post category:Press Release
Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million Post published:February 1, 2022 Post category:Press Release
Small Pharma Reports Fiscal Third Quarter 2021 Highlights Post published:January 31, 2022 Post category:Press Release
Psychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial; More Psychedelic Drug Policy Reform Efforts Emerge Post published:January 28, 2022 Post category:Psychedelic Bulletin
Red Light Holland’s Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program Post published:January 28, 2022 Post category:Press Release
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada Post published:January 27, 2022 Post category:Press Release